<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background and Objectives </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the toxicity and efficacy of reduced intensity conditioning followed by allogeneic stem cell transplantation in 50 patients over 50 years old or with relative contraindications against myeloablative regimens </plain></SENT>
<SENT sid="2" pm="."><plain>Diagnoses were <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=15), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n=9), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (n=9), <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=11) and refractory <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (n=6) </plain></SENT>
<SENT sid="3" pm="."><plain>Design and Methods </plain></SENT>
<SENT sid="4" pm="."><plain>Donors were identical siblings (n=25), non-identical family members (n=6) and unrelated volunteers (n=19) </plain></SENT>
<SENT sid="5" pm="."><plain>Peripheral blood stem cells (n=36) or bone marrow (n=14) were transplanted </plain></SENT>
<SENT sid="6" pm="."><plain>The conditioning regimen consisted of fludarabine 180 mg/m(2), busulphan 8 mg/kg and rabbit antithymocyte globulin 40 mg/kg (Fresenius) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis was carried out with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CSA) alone (n=17) or in combination with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (n=18) or <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (n=15) </plain></SENT>
<SENT sid="8" pm="."><plain>Results </plain></SENT>
<SENT sid="9" pm="."><plain>Neutrophil counts &gt;0.5/nL and platelet counts &gt; 20/nL were reached after 17 (range 0-66) and 19 days (range 0-111), respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Three graft failures occurred </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0001945'>Fever</z:hpo> lasted for a median of 2 days (range 0-15) </plain></SENT>
<SENT sid="12" pm="."><plain>Six patients developed <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">veno-occlusive disease of the liver</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD grade II-IV occurred in 47% of the patients and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in 46% </plain></SENT>
<SENT sid="14" pm="."><plain>The 1-year overall survival probability was 44% (95% CI: 30-58%) </plain></SENT>
<SENT sid="15" pm="."><plain>GVHD-related complications were a major cause of the probability of 1-year non-relapse mortality of 31% (95% CI: 16-46%) </plain></SENT>
<SENT sid="16" pm="."><plain>Interpretation and Conclusions </plain></SENT>
<SENT sid="17" pm="."><plain>In conclusion, the regimen itself can be carried out safely in patients with relative contraindications against myeloablative conditioning </plain></SENT>
<SENT sid="18" pm="."><plain>However, GVHD causes significant non-relapse mortality in high risk patients </plain></SENT>
</text></document>